Evidence map›Paper›PMID 32047231›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.

David S Williams, Dmitri Mouradov, Marsali R Newman, Elham Amini, David K Nickless, Catherine G Fang, Michelle Palmieri, Anuratha Sakthianandeswaren, Shan Li, Robyn L Ward and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

David S WilliamsDepartment of Pathology, Austin Health, Heidelberg, VIC, Australia.
Dmitri MouradovPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.
Marsali R NewmanDepartment of Pathology, Austin Health, Heidelberg, VIC, Australia.
Elham AminiClinipath Pathology, Sonic Healthcare, Perth, WA, Australia.
David K NicklessMelbourne Pathology, Cabrini Health, Malvern, VIC, Australia.
Catherine G FangOlivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.
Michelle PalmieriPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.
Anuratha SakthianandeswarenPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.
Shan LiPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.
Robyn L WardPrince of Wales Clinical School and Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia.
Nicholas J HawkinsSchool of Medical Sciences, UNSW Sydney, Sydney, NSW, Australia.
Iain SkinnerDepartment of Surgery, Western Health, Footscray, VIC, Australia.
Ian JonesDepartment of Surgery, Royal Melbourne Hospital, Parkville, VIC, Australia.
Peter GibbsPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia.
Oliver M SieberPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia. sieber.o@wehi.edu.au.ORCID http://orcid.org/0000-0001-9480-0786
The University of Melbourne · AUAustin Health · AUCabrini Hospital · AUFootscray Hospital · AUOlivia Newton-John Cancer Wellness & Research Centre · AUThe Royal Melbourne Hospital · AUThe University of Queensland · AUThe University of Sydney · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

Austin Medical Research Foundation (AMRF) Project GrantCancer Australia APP1120882Cancer Council Victoria 1060964Department of Health | National Health and Medical Research Council (NHMRC) APP1136119State Government of Victoria (Victorian Government) Operational Infrastructure Support Program
6 · The paper itself

Abstract

Mucinous colorectal adenocarcinoma (CRC) is conventionally defined by extracellular mucin comprising >50% of the tumour area, while tumours with ≤50% mucin are designated as having a mucinous component. However, these definitions are largely arbitrary and comparisons of clinico-molecular features and outcomes by proportion of mucinous component are limited. A cohort of 1643 patients with stage II/III cancer was examined for tumour mucinous component, DNA mismatch repair (MMR) status, BRAF mutation and tumour infiltrating lymphocytes (TILs). Tumours with ≤50% mucinous component exhibited similar characteristics as mucinous tumours, including association with female gender, proximal location, high grade, TIL-high, defective MMR (dMMR) and BRAF mutation. Proportion of mucinous component did not stratify disease-free survival (DFS). In univariate analysis dMMR status, but not histological grade, stratified survival for mucinous and mucinous component tumours; however, in multivariate analysis dMMR status was not an independent predictor. BRAF mutation prognostic value depended on mucinous differentiation and MMR status, with poor prognosis limited to non-mucinous pMMR tumours (HR 2.61, 95% CI 1.69-4.03; p < 0.001). TIL status was a strong independent predictor of DFS in mucinous/mucinous component tumours (HR 0.40, 95% CI 0.23-0.67; p < 0.001), and a superior predictor of prognosis compared with histological grade, MMR and BRAF mutation. Mucinous component and mucinous stage II/III CRCs exhibit clinico-molecular resemblances, with histological grade and BRAF mutation lacking prognostic value. Prognosis for these tumours was instead strongly associated with TIL status, with the most favourable outcomes in TIL-high dMMR tumours, whilst TIL-low tumours had poor outcomes irrespective of MMR status.

Indexed as

Adenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalDNA Mismatch RepairFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID32047231
OpenAlexW3006002241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.